Novartis to pay $440 million for hepatitis C drug
Swiss drug maker, U.S.-based Enanta Pharmaceuticals enter deal
Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.
Post a Comment
Footer Content
Retail Group
Events - Retail
Industry Guides, Research & Reports
International
footer
© 2012 Drug Store News. All Rights Reserved.